TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:50
SCYNEXIS INC ( SCYX ) https://www.scynexis.com
1.87USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
SCYX
19.87%
SPY
30.72%
-73.48%
SCYX
SPY
112.82%
-54.05%
SCYX
SPY
201.04%
SCYX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
81.42
52.55
0.18
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
1.78
0.60
0.89
-57.90
0.00
0.71
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-573.42
78.48
54.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
12.4712
85.35
97.09
2.08
Other Earnings and Cash Flow Stats:
SCYNEXIS INC ( SCYX ) Net Income TTM ($MM) is -113.69
SCYNEXIS INC ( SCYX ) Operating Income TTM ($MM) is -65.06
SCYNEXIS INC ( SCYX ) Owners' Earnings Annual ($MM) is -79.87
SCYNEXIS INC ( SCYX ) Current Price to Owners' Earnings ratio is -0.83
SCYNEXIS INC ( SCYX ) EBITDA TTM ($MM) is -63.69
SCYNEXIS INC ( SCYX ) EBITDA Margin is 54.82%
Capital Allocation:
SCYNEXIS INC ( SCYX ) has paid 0.00 dividends per share and bought back -0.388175 million shares in the past 12 months
SCYNEXIS INC ( SCYX ) has reduced its debt by 22.567 million USD in the last 12 months
Capital Structure:
SCYNEXIS INC ( SCYX ) Interest-bearing Debt ($MM) as of last quarter is 15
SCYNEXIS INC ( SCYX ) Annual Working Capital Investments ($MM) are -53
SCYNEXIS INC ( SCYX ) Book Value ($MM) as of last quarter is 91
SCYNEXIS INC ( SCYX ) Debt/Capital as of last quarter is 16%
Other Balance Sheet Stats:
SCYNEXIS INC ( SCYX ) has 44 million in cash on hand as of last quarter
SCYNEXIS INC ( SCYX ) has 16 million of liabilities due within 12 months, and long term debt 46 as of last quarter
SCYNEXIS INC ( SCYX ) has 47 common shares outstanding as of last quarter
SCYNEXIS INC ( SCYX ) has 0 million USD of preferred stock value
Academic Scores:
SCYNEXIS INC ( SCYX ) Altman Z-Score is 1.15 as of last quarter
SCYNEXIS INC ( SCYX ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
SCYNEXIS INC ( SCYX ) largest shareholder is AMH Equity Ltd owning 234788 shares at 0.44 ($MM) value
Scott Sukenick(an insider) Bought 3500 shares of SCYNEXIS INC ( SCYX ) for the amount of $10500.00 on 2022-04-26
1.40% of SCYNEXIS INC ( SCYX ) is held by insiders, and 48.86% is held by institutions
SCYNEXIS INC ( SCYX ) went public on 2014-05-02
Other SCYNEXIS INC ( SCYX ) financial metrics:
FCF:-51.84
Unlevered Free Cash Flow:-137.59
EPS:-0.15
Operating Margin:-573.42
Gross Profit Margin:78.48
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-7.64
Beta:2.08
Buffet's Owners Earnings:-79.87
Price to Owner's Earnings:-0.83
About SCYNEXIS INC ( SCYX ) :
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.